News

Most US States Ok Medicaid Pilot for Sickle Cell Gene Therapies
Thirty-five states have agreed to participate in a federal pilot program aimed at helping Medicaid patients access costly ...
Crispr Therapeutics Benefits From Diverse Gene Editing Portfolio; Positive Long-Term Outlook
Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...
Sickle Cell Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In April 2025, Kamau Therapeutics announced a study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel ...
Health and Me on MSN4d
How Widespread Is Thalassemia In India—And What Can Be Done?
Thalassemia and sickle cell anaemia are common genetic disorders in India. Early testing, prenatal screening, and improved ...
ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom
CASGEVY became the world's first genome editing therapy to receive marketing authorization, beginning with the United Kingdom ...